Your session is about to expire
← Back to Search
Post-CAR T-cell Therapy Drug Combo for Non-Hodgkin's Lymphoma
Study Summary
This trial tests if a drug combo can help cancer patients after chemo & CAR T-cell therapy. The combo targets cancer cells to help shrink or control them.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I will have a PET-CT scan done within 60 days before starting LD chemotherapy.I have moderate to severe numbness, tingling, or pain in my hands or feet.My DLBCL cancer developed from follicular or marginal zone lymphoma.I have HIV, am on effective treatment, and my viral load is undetectable.I have a history of cancer.I have a tumor larger than 1.5 cm.I had a heart attack or unstable chest pain in the last 6 months.I have a history of disorders related to lymphocyte proliferation.I have CNS lymphoma but no symptoms from it.I have heart symptoms but they don't meet severe criteria.I am 18 years old or older.I have been diagnosed with a specific type of lymphoma.My physical ability is very limited or I am bedridden.My nerve damage does not severely affect my daily activities.I had hepatitis C but have completed treatment, have no liver damage from it, and my viral load is undetectable.I have a history of hepatitis B or C but don't meet certain health criteria.I am eligible for a specific immune therapy according to FDA guidelines.I may have had or can have 'bridging therapy' after a specific cell collection procedure, but not with polatuzumab vedotin or mosunetuzumab.I haven't had cancer in the last 5 years, except for skin cancer.I can take care of myself and am up and about more than 50% of my waking hours.I have received polatuzumab vedotin or mosunetuzumab as treatment.I am considered a candidate for CAR T-cell therapy targeting CD19.I have hepatitis B with no liver damage and am on treatment that controls the virus.
- Group 1: Step I (lymphodepleting chemotherapy)
- Group 2: Step II Arm III (polatuzumab vedotin, mosunetuzumab)
- Group 3: Step II Arm IV (observation)
- Group 4: Step II Arm I (mosunetuzumab)
- Group 5: Step II Arm II (polatuzumab vedotin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any current openings for individuals to participate in this clinical trial?
"Current data on clinicaltrials.gov implies that this research project is actively searching for participants. The trial was initially posted on the 23rd of February 2023 and last modified on 13th March 2021."
What risks are associated with the use of Step II Arm II (polatuzumab vedotin) for patients?
"Taking into account its phase 2 status, Power has rated the safety of Step II Arm II (polatuzumab vedotin) as a 2. Though there is data demonstrating relative safety, no evidence exists to support efficacy."
How many participants have been invited to join the research initiative?
"Affirmative. Clinicaltrials.gov displays that the trial, whose initial posting was on February 23rd 2023 is actively looking for participants. 396 individuals must be enrolled in total from a single location."
Share this study with friends
Copy Link
Messenger